Policy & Regulation
Recruitment Begins in Clinical Trial to Predict Individual Response Prior to Oncology Treatments
22 June 2018 - - Greenville, South Carolina-based research laboratory Kiyatec, Inc. has enrolled the first patients in a US clinical study of its ex vivo 3D drug response assay (EV3D) across several difficult-to-treat solid tumors, the company said.
The 3D-PREDICT Study, initiated at the Cancer Institute of Greenville Health System, is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas.
The study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer.
According to Kiyatec, the primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making.
The EV3D assay platform assesses a patient's own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type.
Kiyatec's mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins by utilizing the patient's own living tumor cells to create functional 3D models to test a battery of cancer therapies.
The goal is to personalize medicine by enabling physicians to isolate only the effective treatments for patients as quickly as possible.
Login
Username:

Password: